Drug Safety

      Turns out you can directly degrade NETs. Holy smokes

      NETs critical in pathology of SLE & other dx
      They’ve found y

      David Liew drdavidliew

      6 days 6 hours ago
      Turns out you can directly degrade NETs. Holy smokes NETs critical in pathology of SLE & other dx They’ve found you can target it Enzymatic degrader fused to albumin Proof-of-concept: degraded a patient’s SLE manifestations in hours Definitely one to watch #ACR25 LB22 @RheumNow https://t.co/HVEt8wFYmI
      Effectiveness of b/tsDMARDs RA pts kidney dysfunction

      CorEvitas RA registry 9,569 pts
      Pts low eGFR = older more comorbi

      Aurelie Najm AurelieRheumo

      6 days 6 hours ago
      Effectiveness of b/tsDMARDs RA pts kidney dysfunction CorEvitas RA registry 9,569 pts Pts low eGFR = older more comorbidities less NSAIDs Reduced eGFR = 30% less likely to achieve remission Persists indeed of GC intake Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg
      Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) ar

      Antoni Chan MD (Prof) synovialjoints

      6 days 6 hours ago

      Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

      Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff)

      Wk 12 Primary Endpoint met
      Mean change DAS28-CRP at Wk 1

      Aurelie Najm AurelieRheumo

      6 days 6 hours ago
      Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 12 SC rosnilimab 100mg Q4W -2.06 400mg Q4W -2.12 600mg Q2W -2.06 PBO -1.69 >90% peripheral and synovial depletion pathogenic T cells 28 Wk Safety profile: https://t.co/XyVhJamFdp
      Not all RA meds are equal for the heart.

      In >10K older adults w/ RA, advanced therapies lowered MACE risk (HR 0.63)

      Jiha Lee JihaRheum

      6 days 6 hours ago
      Not all RA meds are equal for the heart. In >10K older adults w/ RA, advanced therapies lowered MACE risk (HR 0.63) vs csDMARDs, while GCs ↑ risk (HR 1.54) and undertreatment ↑ it 13-fold. Control inflammation, protect the heart. @RheumNow #ACR25 Abstract #2642
      #ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16.

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 6 hours ago
      #ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev
      In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radi

      Antoni Chan MD (Prof) synovialjoints

      6 days 6 hours ago
      In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ
      Questions #ACR25 LB20 to Paul Emery on rosnilimab:
      Fleischmann: could be induction therapy? (Not intent, but could be)
      C

      David Liew drdavidliew

      6 days 6 hours ago
      Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) Choy: Depth of changes with translational data Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi) @RheumNow
      Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic bene

      Richard Conway RichardPAConway

      6 days 6 hours ago
      Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8
      PD-1 agonist as an induction therapy in refractory RA??

      Rosnilimab ph2b:
      - still responding 3mo after Rx stopped
      - no d

      David Liew drdavidliew

      6 days 6 hours ago
      PD-1 agonist as an induction therapy in refractory RA?? Rosnilimab ph2b: - still responding 3mo after Rx stopped - no difference between type of prior b/tsDMARD failure - safety here looks good *so far* A lot of cautious excitement in the room for this #ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N
      A new approach in RA:

      Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pa

      Jiha Lee JihaRheum

      6 days 6 hours ago
      A new approach in RA: Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety. @RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 6 hours ago
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients.

      Richard Conway RichardPAConway

      6 days 6 hours ago
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk
      b/tsDMARD in RA + CKD (eGFR <60)

      From >12K pts in CorEvitas:
      - overall effective but 30% ↓ CDAI-emission (HR 0.

      Jiha Lee JihaRheum

      6 days 6 hours ago
      b/tsDMARD in RA + CKD (eGFR <60) From >12K pts in CorEvitas: - overall effective but 30% ↓ CDAI-emission (HR 0.71) - Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi @RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA
      T Cell Engagers: Are we engaged?
      6 days 6 hours ago

      Podcasts

      • ACR 2025 Daily Podcasts Day2d

      Catch up on Conference Podcasts

      ×